Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment

References

• GoldmanJMeloJChronic myeloid leukemia – advances in biology and new approaches to treatmentN Engl J Med2003349151451146414534339
   PubMed Web of Science ®Google Scholar
• DeiningerMWO’BrienSGGuilhotFInternational randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract 1126]Blood2009114
   Web of Science ®Google Scholar
• BaccaraniMDeiningerMWRostiGEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood2013122687288423803709
   PubMed Web of Science ®Google Scholar
• LarsonRAHochhausAHughesTPNilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upLeukemia2012262197220322699418
   PubMed Web of Science ®Google Scholar
• KantarjianHMShahNPCortesJEDasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)Blood20121191123112922160483
   PubMed Web of Science ®Google Scholar
• HochhausAO’BrienSGGuilhotFSix-year follow-up of patients receiving imatinib for the firstline treatment of chronic myeloid leukemiaLeukemia2009231054106119282833
   PubMed Web of Science ®Google Scholar
• KantarjianHShahNPHochhausADasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med20103622260227020525995
   PubMed Web of Science ®Google Scholar
• CellaDNowinskiCJFrankfurtOThe impact of symptom burden on patient quality of life in chronic myeloid leukemiaOncology20148713314725012261
   PubMed Web of Science ®Google Scholar
• NoensLvan LierdeMADe BockRPrevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO studyBlood20091135401541119349618
   PubMed Web of Science ®Google Scholar
• MarinDBazeosAMahonFXAdherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibJ Clin Oncol2010282381238820385986
   PubMed Web of Science ®Google Scholar
• IbrahimAREliassonLApperleyJFPoor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyBlood20111173733373621346253
   PubMed Web of Science ®Google Scholar
• KekäleMTalvensaariKKoskenvesaPPorkkaKAiraksinenMChronic myeloid leukemia patients’ adherence to per oral tyrosine kinase inhibitors compared with adherence as estimated by their physiciansPatient Prefer Adherence201481619162725473270
   PubMed Web of Science ®Google Scholar
• YoodMUOliveriaSACzirakyMAdherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemiaCurr Med Res Opin201228221321922168217
   PubMed Web of Science ®Google Scholar
• EliassonLCliffordSBarberNMarinDExploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribedLeuk Res20113562663021095002
   PubMed Web of Science ®Google Scholar
• TraskPCCellaDPowellCHealth related quality of life in chronic myeloid leukemiaLeuk Res20133791323116602
   PubMed Web of Science ®Google Scholar
• PhillipsKMPinilla-IbarzJSotomayorEQuality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparisonSupport Care Cancer20132141097110323179489
   PubMed Web of Science ®Google Scholar
• EfficaceFBrecciaMSausseleSWhich health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC quality of life groupAnn Hematol2012911371138122543826
   PubMed Web of Science ®Google Scholar
• AzizZIqbalJAaqibMAssessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemiaLeuk Lymphoma2011521017102321534871
   PubMed Web of Science ®Google Scholar
• US Food Drug Administration: Guidance for IndustryPatient-reported Outcome Measures: Use in Medical Product Development to Support Labeling ClaimsWashington, DCU.S. Department of Health and Human Services, Food and Drug Administration2009
   Google Scholar
• EfficaceFCocksKBrecciaMTime for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomesCrit Rev Oncol Hematol20128112313521435899
   PubMed Web of Science ®Google Scholar
• LaugsandEASprangersMABjordalKHealth care providers underestimate symptom intensities of cancer patients: a multicenter European studyHealth Qual Life Outcomes2010810420858248
   PubMed Web of Science ®Google Scholar
• MoriskyDEAngAKrousel-WoodMPredictive validity of a medication adherence measure in an outpatient settingJ Clin Hypertens200810348354
   PubMed Web of Science ®Google Scholar
• GuyattGHFerransCEHalyardMYExploration of the value of health-related quality-of-life information from clinical research and into clinical practiceMayo Clin Proc2007821229123917908529
   PubMed Web of Science ®Google Scholar
• HahnEAGlendenningGASorensenMVQuality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS StudyJ Clin Oncol2003212138214612775739
   PubMed Web of Science ®Google Scholar
• BaschEJiaXHellerGAdverse symptom event reporting by patients vs clinicians: relationships with clinical outcomesJ Natl Cancer Inst20091011624163219920223
   PubMed Web of Science ®Google Scholar
• M.D. Anderson Cancer Center: The MD Anderson Symptom Inventory Chronic Myeloid Leukemia Module (MDASI-CML) Available from: http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/mdasi-cml.htmlAccessed March 18, 2014
   Google Scholar
• WilliamsLGarcia GonzalezAAultPMeasuring the symptom burden associated with the treatment of chronic myeloid leukemiaBlood2013122564164723777764
   PubMed Web of Science ®Google Scholar
• EfficaceFBaccaraniMBrecciaMInternational development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24Qual Life Res201423382583624026634
   PubMed Web of Science ®Google Scholar